Liquidia Corp (NasdaqCM:LQDA) Q3 2025 Earnings Call November 03, 2025 08:30 AM ET Speaker5Good morning and welcome to the Liquidia Corporation Third Quarter 2025 Financial Results and Corporate Update Conference call. My name is Carmen, and I will be your operator today. All participants are currently in analytics-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions for joining the queue will be provided at that time. Please note that today's call is being recor ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Liquidia Corporation 3Q2025 Earnings & Corporate Update November 3, 2025 ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 2 Use of Non-GAAP Financial Information This presentation includes U.S. Generally Accepted Accounting Principles (GAAP) and non-GAAP financial measures. The section titled "Reconciliation of Non-GAAP Financial Information" in this presentation provides reconciliations to the most directly comparable GAAP financial measure. Non-GAAP financial measures should not be considered in isolation o ...

MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company’s executive leadership team will be providing updates on the company's business during fireside chats at the following two investor conferences in November: 2025 UBS Global Healthcare Conference on Monday, November 10 beginning at 4:15 p.m. ET in Palm Beach Garden ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) | Delaware | 85-1710962 | ...

Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update MORRISVILLE, N.C., November 3, 2025 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on November 3, 2025, to review financial per ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and 1,500 patient starts to dateCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, ...

PresentationRoger JeffsCEO & Director Well, great. Thank you, everybody, for being seated. Welcome. I'm Roger Jeffs, CEO of Liquidia, and welcome to our first ever R&D Day. We're really excited about what we're able to share with you today. I also want to recognize that we have a large number of our leadership team here. And I think if you have questions after the event and you'd like to speak with them individually, please do. So today's presentation, as you know, will include a number of forward-looking ...

Liquidia Corp (LQDA) 2025年研发日电话会议纪要分析 涉及的行业与公司 * 会议聚焦于肺动脉高压（PAH）和间质性肺病相关肺动脉高压（PH-ILD）的治疗领域[1][11][14] * 核心公司为Liquidia Corp，其讨论的产品包括已获批的吸入式曲前列尼尔干粉制剂Yutrepia（研究代码L606）以及处于研发阶段的脂质体缓释吸入混悬液L606[1][5][11][90] * 会议邀请了来自加州大学洛杉矶分校（UCLA）和南佛罗里达大学的顶尖肺血管疾病专家作为主讲嘉宾[7][8][9][10][111] 核心观点与论据 Yutrepia（L606）的产品优势与临床数据 * Yutrepia被定位为当前最优的吸入式曲前列尼尔疗法，其优势在于靶向肺部递送、便携式装置、良好的耐受性、宽范围的剂量可滴定性[3][4][5] * ASCENT研究（PH-ILD患者）24周数据显示，中位剂量达到185.5微克（相当于Tyvaso nebulized 21吸/次），70%以上患者完成研究，停药率为27.8%，无因治疗相关不良事件导致的停药[45][52][53][66] * 在ASCENT研究中，咳嗽是最常见不良事件（约40-50%），但绝大多数为轻度，且未导致停药；研究中位六分钟步行距离改善在24周时达到41米，超过30米的临床意义阈值[67][68][71][72][75] * 真实世界使用经验（获批5个月）证实了其在PH-ILD患者中的良好耐受性和可滴定性，专家表示已基本用Yutrepia替代Tyvaso DPI用于PH-ILD患者[79][80][159][160][161][228][229][241][242] L606（脂质体缓释制剂）的研发进展与潜力 * L606旨在通过脂质体技术实现缓释，将给药频率从每日四次（QID）减少到每日两次（BID），以提供更稳定的24小时药物暴露[5][89][90][93] * Phase I健康受试者研究显示，与Tyvaso相比，L606在相似AUC下，Cmax降低了7倍，提示更好的系统耐受性潜力；咳嗽发生率显著更低（L606 8% vs Tyvaso 66%）[105][106][107] * 美国开放标签研究（28名患者，48周）数据显示，L606耐受性良好，35%的治疗期不良事件与治疗相关，无治疗相关严重不良事件；咳嗽发生率为32%，其中仅14.3%被认为与治疗相关且均为轻度[119][120][127][128] * 该研究探索性终点显示，48周时六分钟步行距离中位改善为22.5米，且波谷与波峰步行距离差异极小，支持其缓释特性带来的24小时稳定暴露[129][130][131][132] 肺动脉高压（PAH/PH-ILD）的治疗现状与趋势 * 专家强调早期诊断和治疗的重要性，即使轻度肺动脉高压（如PVR>2伍德单位）也与死亡率增加相关[15][17][18][19][20][21][22] * 前列腺素通路是治疗关键，给药剂量与疗效正相关，更高的药物暴露可能带来更好的长期疾病修正效应[24][28][29][35][38][192][193][194] * 当前治疗趋势是更早启用前列腺素类药物，并且利用耐受性更好的吸入制剂（如Yutrepia）来延迟或避免使用负担较重的肠外前列腺素疗法[36][37][165][166][167][170][172][173][174][176] 其他重要内容 RESPIRE关键性三期试验设计 * L606针对PH-ILD的全球三期试验（RESPIRE）计划招募约344名患者，按1：1随机分组，主要终点为16周时波峰六分钟步行距离的变化，次要终点包括24周时的持久性反应和临床恶化时间[140][142][143][144][145][146] * 试验将允许患者使用背景治疗（如PDE5抑制剂和抗纤维化药物），并采用三种分层方法（是否使用PDE5抑制剂、基线六分钟步行距离是否大于300米、是否为CPFE/PH-ILD）[148][149][150][206][207][209] * 公司与FDA的Type C会议反馈表明，一项成功的PH-ILD三期研究结合现有数据，可能支持L606在PH-ILD和PAH两个适应症的获批[210][211] 装置与便利性 * L606将采用与Philips MetaSize合作的新型FOX振动筛网雾化器，该装置便携（重128克）、电池供电、呼吸驱动，每次给药时间约1分钟[97][98][99][103][178][179][180][189] * 专家认为，对于多数需要吸氧、功能状态受损的PH-ILD患者，疗效和耐受性比单纯的给药途径（DPI vs 雾化器）更重要，但简化、便携的装置对依从性至关重要[185][186][187][188] 市场机会与竞争格局 * PH-ILD是一个未被充分诊断但患病率很高的领域（某些ILD类型中发生率高达86%），存在巨大未满足需求[15][17][18][141] * Yutrepia凭借其耐受性优势，正在快速改变PH-ILD的治疗格局，专家临床实践已显著转向使用Yutrepia[159][160][161][228][229][241][242] * L606若成功，有望通过BID给药和更优的药代动力学特征，成为下一代吸入式曲前列尼尔疗法的领导者[5][89][136][215][216]